Back to Archived Journals » Biosimilars » Volume 5 » default

Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Archive: Volume 5, 2015

Label-free interaction analysis as a tool to demonstrate biosimilarity of therapeutic monoclonal antibodies

Sinha-Datta U, Khan S, Wadgaonkar D

Biosimilars 2015, 5:83-91

Published Date: 16 September 2015

Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study

Cuevas C, Deisenhammer F, You X, Scolnik M, Buffels R, Sperling B, Flores-Ramírez F, Macías-Islas M, Sauri-Suárez S

Biosimilars 2015, 5:75-81

Published Date: 15 September 2015

Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta

Mikhail A, Brown C

Biosimilars 2015, 5:65-73

Published Date: 9 September 2015

Clinical trials in the development of biosimilars: future considerations

Huneycutt BJ, Gillespie E, Woollett GR

Biosimilars 2015, 5:49-63

Published Date: 9 July 2015

Challenging issues in assessing analytical similarity in biosimilar studies

Chow SC

Biosimilars 2015, 5:33-39

Published Date: 22 May 2015

Global regulatory landscape of biosimilars: emerging and established market perspectives

Krishnan A, Mody R, Malhotra H

Biosimilars 2015, 5:19-32

Published Date: 17 February 2015

Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197

Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK

Biosimilars 2015, 5:1-18

Published Date: 31 December 2014